IMPC phenotypes (gene matching)
B6;129S2-Dusp1tm1Brv/Cnbc
| Status | Available to order |
| EMMA ID | EM:14604 |
| International strain name | B6;129S2-Dusp1tm1Brv/Cnbc |
| Alternative name | Dusp1tm1Brv |
| Strain type | Targeted Mutant Strains : Knock-out |
| Allele/Transgene symbol | Dusp1tm1Brv |
| Gene/Transgene symbol | Dusp1 |
Information from provider
| Provider | Isabel Varela Nieto |
| Provider affiliation | Fisiopatología Endocrina y del Sistema Nervioso, Instituto de Investigaciones Biomédicas "Alberto Sols" |
| Additional owner | Dr. Rodrigo Bravo, Department of Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA |
| Genetic information | Exon 2 of Dusp1 gene was disrupted by the insertion of a neomycin selection cassette inserted by homologous recombination. (Dorfman et al. Oncogene. 1996 Sep 5;13(5):925-31). |
| Phenotypic information | Homozygous:Deficient mice are born at normal frequency and are fertile (Dorfman et al., 1996). Dusp1-/- mice exhibited increased inflammatory response and bacterial clearance was impaired in homozygous mice, which displayed increased mortality (Hammer et al., 2010). Dusp1 deficiency accelerates the onset and the progression of age-related hearing loss (Celaya et al., 2019). Dusp1 -/- mice exhibited premature and progressive sensorineural hearing loss, with total deafness by age 12 months. Dusp1 deficiency generated a redox imbalance in young mice, which increased the levels of reactive oxygen species, leading to DNA damage and cochlear cell loss due to apoptosis. Progressive hearing loss also correlated with inflammatory dysregulation, as Dusp1 deficit increased macrophage infiltration, with an exacerbated cochlear inflammatory response in Dusp1-/- mice (Celaya et al., 2019).Heterozygous:Dusp1 heterozygous mice showed no differences in ABR thresholds when comparing with wild type mice at 8-month-old (Celaya et al., 2019). |
| Breeding history | Strain of origin 129S2/SvPas backcrossed twice to C57BL/6Crl. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
| Animals used for archiving | heterozygous 129/SvPas |
Disease and phenotype information
MGI phenotypes (gene matching)
- increased granulocyte number / MGI
- small liver / MGI
- abnormal myogenesis / MGI
- abnormal muscle development / MGI
- abnormal muscle regeneration / MGI
- abnormal superior cervical ganglion morphology / MGI
- thick pulmonary interalveolar septum / MGI
- decreased body weight / MGI
- weight loss / MGI
- decreased anxiety-related response / MGI
- abnormal eating behavior / MGI
- abnormal circulating alanine transaminase level / MGI
- hypotension / MGI
- lung inflammation / MGI
- decreased susceptibility to hepatic steatosis / MGI
- increased susceptibility to bacterial infection / MGI
- abnormal innate immunity / MGI
- decreased circulating triglyceride level / MGI
- decreased circulating free fatty acid level / MGI
- decreased circulating alanine transaminase level / MGI
- abnormal cytokine secretion / MGI
- increased neuron apoptosis / MGI
- decreased susceptibility to age related obesity / MGI
- abnormal locomotor activation / MGI
- abnormal depression-related behavior / MGI
- abnormal gluconeogenesis / MGI
- decreased liver weight / MGI
- increased susceptibility to induced arthritis / MGI
- pulmonary edema / MGI
- abnormal nitric oxide homeostasis / MGI
- increased energy expenditure / MGI
- decreased circulating cholesterol level / MGI
- homeostasis/metabolism phenotype / MGI
- immune system phenotype / MGI
- decreased body temperature / MGI
- increased blood urea nitrogen level / MGI
- increased susceptibility to type I hypersensitivity reaction / MGI
- decreased susceptibility to diet-induced obesity / MGI
- decreased systemic arterial systolic blood pressure / MGI
- abnormal dendrite morphology / MGI
- increased circulating tumor necrosis factor level / MGI
- increased tumor necrosis factor secretion / MGI
- increased circulating interferon-gamma level / MGI
- increased circulating interleukin-10 level / MGI
- increased circulating interleukin-6 level / MGI
- increased interleukin-1 beta secretion / MGI
- increased interleukin-6 secretion / MGI
- abnormal chemokine level / MGI
- abnormal chemokine secretion / MGI
- increased susceptibility to endotoxin shock / MGI
- abnormal interleukin level / MGI
- increased mast cell degranulation / MGI
- decreased fat cell size / MGI
- decreased abdominal fat pad weight / MGI
- decreased epididymal fat pad weight / MGI
- decreased skeletal muscle fiber size / MGI
- decreased skeletal muscle fiber diameter / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- increased sensitivity to xenobiotic induced morbidity/mortality / MGI
- increased prostaglandin level / MGI
- decreased total body fat amount / MGI
- increased respiratory quotient / MGI
- abnormal cellular respiration / MGI
Literature references
- Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts.;Dorfman K, Carrasco D, Gruda M, Ryan C, Lira S A, Bravo R, ;1996;Oncogene;13;925-31; 8806681
- Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss.;Celaya Adelaida M, Sánchez-Pérez Isabel, Bermúdez-Muñoz Jose M, Rodríguez-de la Rosa Lourdes, Pintado-Berninches Laura, Perona Rosario, Murillo-Cuesta Silvia, Varela-Nieto Isabel, ;2019;eLife;8;; 30938680